Details of the Drug
General Information of Drug (ID: DM27KFY)
| Drug Name |
SB-207266A
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Piboserod hydrochloride; Piboserod HCl; Piboserod (hydrochloride); 178273-87-5; UNII-61Z0VMM0AJ; SB 207266A; 61Z0VMM0AJ; Piboserod hydrochloride [USAN]; SB-207266-A; Piboserod hydrochloride (USAN); N-[(1-Butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide monohydrochloride; SB 207266 hydrochloride; SB-207266A; AC1L42ON; MLS006010278; SCHEMBL2228911; CHEMBL2106927; DTXSID40170453; UABVCZHWRUGYSR-UHFFFAOYSA-N; MolPort-042-665-633; HY-15574A; AKOS030526663; API0004730; SMR004701348; FT-0724495; D05471
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 |
Molecular Weight | 406 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
| Rotatable Bond Count | 6 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Irritable bowel syndrome | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | DD91.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


